Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial

S. Hideaki, K. Chika, K. Ryou (Nagasaki, Japan)

Source: Annual Congress 2008 - Physiological response to exercise performance
Session: Physiological response to exercise performance
Session type: E-Communication Session
Number: 3303
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Hideaki, K. Chika, K. Ryou (Nagasaki, Japan). Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial. Eur Respir J 2008; 32: Suppl. 52, 3303

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial
Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases
Year: 2020


A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study
Source: Eur Respir J 2003; 22: Suppl. 45, 49s
Year: 2003

A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


Effect of oral beta-alanine supplementation on muscle carnosine in patients with COPD: A double blind, placebo-controlled, randomized trial
Source: Virtual Congress 2020 – Muscle, exercise capacity and symptoms of chronic lung disease: a physio update
Year: 2020




A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics
Source: International Congress 2017 – Novel studies on bronchodilators and cough
Year: 2017



A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics.
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010